The Behavioral Medicine Report

Ovarian and breast cancer treatments being developed that mix a protein inhibitor and traditional anticancer drugs are showing signs of success, according to a new review for Faculty of 1000 Biology Reports. Susan Bates and Christina Annunziata looked at several recent papers on this form of treatment, which takes advantage of the synthetic lethality of BRCA (breast cancer susceptibility genes) and poly-ADP ribose polymerase (PARP) proteins to attack cancerous cells whilst sparing healthy ones.

BRCA and PARP are two key players in DNA repair and have different but complementary functions in the cell. Loss of the BRCA protein still allows the cell to survive but greatly increases its chances of becoming cancerous through the accumulation of mutations. The loss of both proteins, however, kills the cell in a process called synthetic lethality.

This shows the mechanism of sensitivity to PARP inhibition in BRCA-deficient cells. Credit: Susan E Bates; F1000 Biology Reports

Researchers, by using drugs to block the activity of PARP in cells missing BRCA, such as those found in certain breast and ovarian cancers, can help spare healthy, non-cancerous cells because they have functional BRCA and are not affected by the loss of PARP. Thus, only cancer cells without functional BRCA protein are killed by drugs that inhibit PARP.

Recent clinical trials have shown that cancers caused by mutations that knock out BRCA activity can be controlled by blocking PARP activity with specific drugs. Patients were treated with traditional anticancer drugs alone or in combination with one of two new PARP inhibitors, olaparib or BSI-201.

Bates notes that patients on combination therapy had improved “[disease] progression-free survival, and overall survival” as compared to patients treated with traditional drugs alone.

Bates is optimistic about the promise of combining PARP inhibitors with existing cancer drugs. She says that the results of these clinical trials “have provided proof of principle in achieving synthetic lethality” with PARP-inhibiting drugs and that treatments combining novel PARP inhibitors with traditional chemotherapeutic drugs have the potential to vanquish BRCA-associated breast and ovarian cancers.

Material adapted from Faculty of 1000: Biology and Medicine by CFisher.

1. Natural Compounds In Pomegranates May Prevent Growth Of Hormone-Dependent Breast Cancer
2. Group Therapy Improves Survival in Women With Breast Cancer
3. Annual Report To The Nation Finds Continued Declines In Overall Cancer Rates
4. Daughter Cells Send Dirty Laundry Home To Mom
5. First Evidence That Native Dendritic Cells Of The Brain Can Muster An Immune Response